RESI Innovation Challenge
RESI Boston 2018 Innovation Challenge Companies
First Coast Innovation Challenge
All eligible tech hub members from DC through Boston are also invited to apply to the First Coast Innovation Challenge and have the chance to pitch your technologies to a panel of investors.
- 8 finalists from tech hubs will be selected to pitch to a panel of investors
- Boost your exposure to 400 investors
- All finalists will be featured in the program guide, on the RESI website and announced in LSN’s newsletter to a readership of 20,000+
- Present your technology in a poster board format with your tech hub
- Special registration rate: $300 (with your tech hub discount code)
- Full access to partnering platform, investor panels, entrepreneur workshops and exhibit hall
- It is FREE to apply
First Coast Innovation Challenge Application Deadline Extended to August 17th, 2018
Taiwan Resonant Waves Research Corp. (TRWR) was founded in 2010 in the capital of Taiwan – Taipei. Integrating innovative bioelectronic technology with non-invasive medical devices, we are dedicated to helping patients with chronic diseases better manage health-related challenges.There is unlimited promise in the application of Bioelectrical medicine in the treatment of chronic diseases. Designed and developed by TRWR, Microcurrent Electrical Nerve Stimulation technology (MENS) is currently being used as a non-invasive, physical approach to treating and alleviating symptoms associated with diabetes (such as decreasing HbA1c of Type 2 Diabetes Mellitus patient). Our vision is to lead the world in groundbreaking research and development in electroceutical technology as a means of enhancing quality of life, without the adverse side effects of conventional approaches.
Our laser-based sensor is many times more accurate than conventional laser and is able to detect even low concentrations of bacteria based on its movements in real-time. Even though our first application targets water, we have managed to decrease antibiotics susceptibility test from 10-15 hours to less than 1 hour.
Taipeibio is an R&D-driven company with core technology derived from Harvard and MIT; which focuses on tissue regeneration and repairs various bone defects including alveolar bone, bone, joint, ligament and cartilage. Taipeibio has comprehensive global IP protection in over 45 countries (Fish & Richardson; Cesari & McKenna). Taipeibio has established 3 core labs and 5 research arms to support product development with 2 governmental funding programs . Taipeibio has accumulated over 160 successful clinical cases with 14 years stress-bearing data to prove safety and efficacy. The cartilage regeneration product has been proved to repair large articular cartilages and difficult TMJ defects in a rabbit model. Relative scientific reports were published in high-impact SCI journals. The products will be made in U.S.A. and aiming FDA approval.